Comparison of naltrexone, 6α-naltrexol, and 6β-naltrexol in morphine-dependent and in nondependent rhesus monkeys

Jun Xu Li, Lance R. McMahon, Charles P France

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Rationale: Some opioid receptor ligands that appear to be neutral antagonists can have inverse agonist activity under conditions of increased constitutive activity (e.g., agonist treatment). Objectives: This study compared the opioid receptor antagonist naltrexone and its metabolites 6α-naltrexol and 6β-naltrexol in nondependent and morphine-dependent monkeys to see whether their potencies varied according to drug treatment and, presumably, to differences in constitutive activity of μ opioid receptors. Results: In monkeys (n=4) receiving 3.2 mg/kg per day of morphine and discriminating 0.0178 mg/kg naltrexone, naltrexone and each metabolite increased responding on the naltrexone lever in a dose-related manner with naltrexone being 8- and 71-fold more potent than 6α- and 6β-naltrexol, respectively. After 27 h of no-morphine treatment, monkeys responded on the naltrexone lever, and this effect was reversed by morphine. Naltrexone and each metabolite prevented morphine reversal of naltrexone-lever responding, and their rank order potency was the same as their substitution for naltrexone; however, the potency between naltrexone and each metabolite was slightly greater in morphine-dependent as compared to morphine-deprived monkeys. In a separate group (n=3) of nondependent monkeys discriminating 1.78 mg/kg of morphine, all three compounds antagonized morphine with the same potency as in the reversal study (morphine-dependent monkeys), with Schild analyses showing no difference in apparent affinities (pA 2) between nondependent and morphine-dependent monkeys. Conclusion: Naltrexone and 6α- and 6β-naltrexol have qualitatively similar effects, and their potencies do not vary markedly with opioid treatment, suggesting that under these conditions, they do not vary with regard to inverse agonism.

Original languageEnglish (US)
Pages (from-to)479-486
Number of pages8
JournalPsychopharmacology
Volume195
Issue number4
DOIs
StatePublished - Jan 2008

Fingerprint

Naltrexone
Macaca mulatta
Morphine
Haplorhini
Opioid Receptors
6 beta-hydroxynaltrexone
Narcotic Antagonists
Opioid Analgesics
Ligands

Keywords

  • Antagonism
  • Dependence
  • Drug discrimination
  • Monkey
  • Naltrexol
  • Naltrexone
  • Opioid
  • Schild analysis

ASJC Scopus subject areas

  • Pharmacology

Cite this

Comparison of naltrexone, 6α-naltrexol, and 6β-naltrexol in morphine-dependent and in nondependent rhesus monkeys. / Li, Jun Xu; McMahon, Lance R.; France, Charles P.

In: Psychopharmacology, Vol. 195, No. 4, 01.2008, p. 479-486.

Research output: Contribution to journalArticle

@article{f74c79b7cb044cfa8ad0e4de8bc4bb0b,
title = "Comparison of naltrexone, 6α-naltrexol, and 6β-naltrexol in morphine-dependent and in nondependent rhesus monkeys",
abstract = "Rationale: Some opioid receptor ligands that appear to be neutral antagonists can have inverse agonist activity under conditions of increased constitutive activity (e.g., agonist treatment). Objectives: This study compared the opioid receptor antagonist naltrexone and its metabolites 6α-naltrexol and 6β-naltrexol in nondependent and morphine-dependent monkeys to see whether their potencies varied according to drug treatment and, presumably, to differences in constitutive activity of μ opioid receptors. Results: In monkeys (n=4) receiving 3.2 mg/kg per day of morphine and discriminating 0.0178 mg/kg naltrexone, naltrexone and each metabolite increased responding on the naltrexone lever in a dose-related manner with naltrexone being 8- and 71-fold more potent than 6α- and 6β-naltrexol, respectively. After 27 h of no-morphine treatment, monkeys responded on the naltrexone lever, and this effect was reversed by morphine. Naltrexone and each metabolite prevented morphine reversal of naltrexone-lever responding, and their rank order potency was the same as their substitution for naltrexone; however, the potency between naltrexone and each metabolite was slightly greater in morphine-dependent as compared to morphine-deprived monkeys. In a separate group (n=3) of nondependent monkeys discriminating 1.78 mg/kg of morphine, all three compounds antagonized morphine with the same potency as in the reversal study (morphine-dependent monkeys), with Schild analyses showing no difference in apparent affinities (pA 2) between nondependent and morphine-dependent monkeys. Conclusion: Naltrexone and 6α- and 6β-naltrexol have qualitatively similar effects, and their potencies do not vary markedly with opioid treatment, suggesting that under these conditions, they do not vary with regard to inverse agonism.",
keywords = "Antagonism, Dependence, Drug discrimination, Monkey, Naltrexol, Naltrexone, Opioid, Schild analysis",
author = "Li, {Jun Xu} and McMahon, {Lance R.} and France, {Charles P}",
year = "2008",
month = "1",
doi = "10.1007/s00213-007-0914-9",
language = "English (US)",
volume = "195",
pages = "479--486",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Comparison of naltrexone, 6α-naltrexol, and 6β-naltrexol in morphine-dependent and in nondependent rhesus monkeys

AU - Li, Jun Xu

AU - McMahon, Lance R.

AU - France, Charles P

PY - 2008/1

Y1 - 2008/1

N2 - Rationale: Some opioid receptor ligands that appear to be neutral antagonists can have inverse agonist activity under conditions of increased constitutive activity (e.g., agonist treatment). Objectives: This study compared the opioid receptor antagonist naltrexone and its metabolites 6α-naltrexol and 6β-naltrexol in nondependent and morphine-dependent monkeys to see whether their potencies varied according to drug treatment and, presumably, to differences in constitutive activity of μ opioid receptors. Results: In monkeys (n=4) receiving 3.2 mg/kg per day of morphine and discriminating 0.0178 mg/kg naltrexone, naltrexone and each metabolite increased responding on the naltrexone lever in a dose-related manner with naltrexone being 8- and 71-fold more potent than 6α- and 6β-naltrexol, respectively. After 27 h of no-morphine treatment, monkeys responded on the naltrexone lever, and this effect was reversed by morphine. Naltrexone and each metabolite prevented morphine reversal of naltrexone-lever responding, and their rank order potency was the same as their substitution for naltrexone; however, the potency between naltrexone and each metabolite was slightly greater in morphine-dependent as compared to morphine-deprived monkeys. In a separate group (n=3) of nondependent monkeys discriminating 1.78 mg/kg of morphine, all three compounds antagonized morphine with the same potency as in the reversal study (morphine-dependent monkeys), with Schild analyses showing no difference in apparent affinities (pA 2) between nondependent and morphine-dependent monkeys. Conclusion: Naltrexone and 6α- and 6β-naltrexol have qualitatively similar effects, and their potencies do not vary markedly with opioid treatment, suggesting that under these conditions, they do not vary with regard to inverse agonism.

AB - Rationale: Some opioid receptor ligands that appear to be neutral antagonists can have inverse agonist activity under conditions of increased constitutive activity (e.g., agonist treatment). Objectives: This study compared the opioid receptor antagonist naltrexone and its metabolites 6α-naltrexol and 6β-naltrexol in nondependent and morphine-dependent monkeys to see whether their potencies varied according to drug treatment and, presumably, to differences in constitutive activity of μ opioid receptors. Results: In monkeys (n=4) receiving 3.2 mg/kg per day of morphine and discriminating 0.0178 mg/kg naltrexone, naltrexone and each metabolite increased responding on the naltrexone lever in a dose-related manner with naltrexone being 8- and 71-fold more potent than 6α- and 6β-naltrexol, respectively. After 27 h of no-morphine treatment, monkeys responded on the naltrexone lever, and this effect was reversed by morphine. Naltrexone and each metabolite prevented morphine reversal of naltrexone-lever responding, and their rank order potency was the same as their substitution for naltrexone; however, the potency between naltrexone and each metabolite was slightly greater in morphine-dependent as compared to morphine-deprived monkeys. In a separate group (n=3) of nondependent monkeys discriminating 1.78 mg/kg of morphine, all three compounds antagonized morphine with the same potency as in the reversal study (morphine-dependent monkeys), with Schild analyses showing no difference in apparent affinities (pA 2) between nondependent and morphine-dependent monkeys. Conclusion: Naltrexone and 6α- and 6β-naltrexol have qualitatively similar effects, and their potencies do not vary markedly with opioid treatment, suggesting that under these conditions, they do not vary with regard to inverse agonism.

KW - Antagonism

KW - Dependence

KW - Drug discrimination

KW - Monkey

KW - Naltrexol

KW - Naltrexone

KW - Opioid

KW - Schild analysis

UR - http://www.scopus.com/inward/record.url?scp=36349010310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36349010310&partnerID=8YFLogxK

U2 - 10.1007/s00213-007-0914-9

DO - 10.1007/s00213-007-0914-9

M3 - Article

C2 - 17874317

AN - SCOPUS:36349010310

VL - 195

SP - 479

EP - 486

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 4

ER -